NEW YORK (GenomeWeb News) – Oxford Genome Sciences today said that it has changed its name to Oxford BioTherapeutics.
The Oxford, UK-based firm said the name change comes as it focuses its efforts on the development of its pipeline of antibody-based cancer therapeutics. The firm also has a collaboration with diagnostics firm Biosite to develop companion diagnostics for its cancer therapeutics.
Oxford BioTherapeutics CEO Christian Rohlff said in a statement that the new name “truly embodies the core strategic focus of the company on the development of successful antibody-based drugs for cancer, with integrated diagnostics.”
OGS was formed in 2004 by the proteomics products team from Oxford GlycoSciences, which closed that part of its business after its acquisition by Celltech in late 2003. OGS’ primary focus had been on helping pharmaceutical companies discover biomarkers and protein targets and to validate biomarkers and drug targets.